系统性硬化症相关肺动脉高压的长期结局:PHAROS登记研究
该研究基于PHAROS前瞻性登记研究,分析160例新发系统性硬化症相关肺动脉高压(SSc-PAH)患者的长期生存。1、3、5、8年总体生存率分别为95%、75%、63%、49%,PAH占全部死亡的52%,且93%的PAH相关死亡发生在诊断后4年内。男性、弥漫性病变及较高的肺动脉压等为死亡预测因素。
要点
- SSc-PAH患者8年总体生存率仅49%,PAH相关死亡多发生在诊断后4年内。
- 男性、弥漫性皮肤病变、较高肺动脉压、较低6分钟步行距离及DLCO预示生存更差。
- 应尽早优化对高早期死亡风险SSc-PAH患者的治疗。
核心结论
- PHAROS登记中SSc-PAH总体生存率高于其他SSc-PAH队列。
- PAH占全部死亡的52%,且主要发生在PAH诊断后最初几年内。
- 优化对早期PAH相关死亡高风险患者的治疗至关重要。
研究设计与样本
- PHAROS为前瞻性登记研究,纳入系统性硬化症患者中经右心导管诊断的新发WHO第1组PAH患者。
- 共分析160例新发SSc-PAH患者,采用Kaplan-Meier曲线评估生存,多因素Cox回归识别死亡预测因素。
主要发现
- 160例新发SSc-PAH患者1、3、5、8年生存率分别为95%、75%、63%、49%。
- PAH占全部死亡的52%;限制于PAH相关死亡时,1、3、5、8年生存率分别为97%、83%、76%、76%。
- 93%的PAH相关死亡发生在诊断后4年内。
- 多因素分析中,男性(HR 3.11;95%CI 1.38-6.98)、弥漫性病变(HR 2.12;95%CI 1.13-3.93)、心电图收缩期肺动脉压(HR 1.06;95%CI 1.01-1.11)、右心导管平均肺动脉压(HR 1.03;95%CI 1.001-1.07)、6分钟步行距离(HR 0.92;95%CI 0.86-0.99)及一氧化碳弥散量(HR 0.65;95%CI 0.46-0.92)显著影响生存。
临床怎么用
- 对SSc-PAH患者应识别男性、弥漫性病变、高肺动脉压、低6分钟步行距离及低DLCO等高危因素。
- 鉴于PAH相关死亡多发生在诊断后4年内,应尽早优化治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pulmonary arterial hypertension (PAH) is a leading cause of death in patients with systemic sclerosis (SSc). The purpose of this study was to assess long-term outcomes in patients with SSc-PAH. METHODS: Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma is a prospective registry of patients with SSc at high risk for or with incident pulmonary hypertension from right heart catheterization. Incident World Health Organization group I PAH patients were analyzed. Kaplan-Meier survival curves were generated for the overall cohort and those who died of PAH. Multivariate Cox regression models identified predictors of mortality. RESULTS: Survival in 160 patients with incident SSc-PAH at 1, 3, 5, and 8 years was 95%, 75%, 63%, and 49%, respectively. PAH accounted for 52% of all deaths. When restricted to deaths from PAH, respective survival rates were 97%, 83%, 76%, and 76%, with 93% of PAH-related deaths occurring within 4 years of diagnosis. Men (hazard ratio [HR], 3.11; 95% CI, 1.38-6.98), diffuse disease (HR, 2.12; 95% CI, 1.13-3.93), systolic pulmonary artery pressure (PAP) on ECG (HR, 1.06 95% CI, 1.01-1.11), mean PAP on right heart catheterization (HR, 1.03; 95% CI, 1.001-1.07), 6-min walk distance (HR, 0.92; 95% CI, 0.86-0.99), and diffusing capacity for carbon monoxide (HR, 0.65; 95% CI, 0.46-0.92) significantly affected survival on multivariate analysis. CONCLUSIONS: Overall survival in PHAROS was higher than other SSc-PAH cohorts. PAH accounted for more than one-half of deaths and primarily within the first few years after PAH diagnosis. Optimization of treatment for those at greatest risk of early PAH-related death is crucial.
引用
- Kolstad KD, Li S, Steen V, et al. Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS). Chest. 2018. PMID: 29777655. doi:10.1016/j.chest.2018.05.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。